Ensysce Biosciences (ENSC) to Post Quarterly Earnings on Wednesday

Ensysce Biosciences (NASDAQ:ENSC) is expected to be issuing its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Ensysce Biosciences to post earnings of ($0.50) per share and revenue of $1.90 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Ensysce Biosciences (NASDAQ:ENSC) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.21. Ensysce Biosciences had a negative net margin of 250.39% and a negative return on equity of 766.45%. The firm had revenue of $0.96 million for the quarter, compared to the consensus estimate of $1.00 million. On average, analysts expect Ensysce Biosciences to post $-2 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Ensysce Biosciences Price Performance

Shares of ENSC stock opened at $0.32 on Wednesday. The company’s fifty day moving average price is $0.28 and its two-hundred day moving average price is $0.43. The firm has a market capitalization of $4.98 million, a P/E ratio of -0.10 and a beta of 0.84. Ensysce Biosciences has a 12 month low of $0.23 and a 12 month high of $2.75.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ensysce Biosciences in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Ensysce Biosciences currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Ensysce Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. grew its position in shares of Ensysce Biosciences by 100.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock worth $138,000 after buying an additional 75,000 shares in the last quarter. DRW Securities LLC raised its holdings in Ensysce Biosciences by 42.4% in the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after acquiring an additional 29,336 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Ensysce Biosciences in the third quarter valued at $34,000. Finally, Virtu Financial LLC bought a new position in Ensysce Biosciences during the 3rd quarter valued at $34,000. 5.63% of the stock is currently owned by hedge funds and other institutional investors.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.